The capsaicinoids are well-known species, wich are able to modify the capsaicin sensitive afferent nerves. Their actions are dose-dependent processes, and they are capable to modify the neurogenic inflammation, pain and defence of the different target organs against different noxious agents. Twenty-one researchers (chemist, pharmaceutical chemist, physicians, pharmaceutics, laboratory experts, biologist, engineers and agricultural engineers) have actively participated in an innovative pharmacological research programme from 2005 to 2008, the aims of which were to produce: new drug combinations for patients with myocardial infarction (orally applicable combinations of capsaicinoids with aspirin) and for those with chronic degenerative locomotive disease (orally applicable capsaicinoids with diclofenac and Naproxen).  In this book, the authors summarized the different agricultural, chemical, physiological, pharmacological, toxicological, national and international jural, patent, pharmaceutical industrial, economical problems in their study programme during the development of new drug combinations of capsaicinoids with the different nonsteroidal anti-inflammatory drugs (NSAIDs) in orally applicable drugs to patients.